Overview of melanoma vaccines and promising approaches.

Published

Journal Article (Review)

It is difficult to envision anything better than melanoma vaccines to exemplify the effectiveness of modern biotechnology in developing biologically rational therapeutics. Melanoma vaccines can reproducibly induce cytotoxic T lymphocyte (CTL) responses better than any other anticancer therapy. Anticancer vaccines have been labeled by some as ineffective for the simple reason that they only rarely lead to cancer regression. This oxymoron stems from the naïve expectation that CTLs are all that is needed to reject cancer. Little is known about requirements for CTL localization and effector function within the tumor microenvironment. In the future, more attention should be given to events downstream of immunization (afferent arm of immune response) to identify combination therapies likely to facilitate localization and activation of CTL at the receiving end (efferent arm).

Full Text

Duke Authors

Cited Authors

  • Panelli, MC; Wang, E; Monsurrò, V; Jin, P; Zavaglia, K; Smith, K; Ngalame, Y; Marincola, FM

Published Date

  • September 2004

Published In

Volume / Issue

  • 6 / 5

Start / End Page

  • 414 - 420

PubMed ID

  • 15291987

Pubmed Central ID

  • 15291987

Electronic International Standard Serial Number (EISSN)

  • 1534-6269

Language

  • eng

Conference Location

  • United States